Brain & Nervous System Cancers..Seattle Cancer Care Alliance
Mast sanity - 22. Oct, 18:04
Sunday, 22. October 2006
Tumour risk associated with use of cellular telephones or cordless desktop telephones
World J Surg Oncol. 2006 Oct 11;4(1):74
[Epub ahead of print]
* Hardell L,
* Hansson Mild K,
* Carlberg M,
* Soderqvist F.
ABSTRACT:
BACKGROUND: The use of cellular and cordless telephones has increased dramatically during the last decade. There is concern of health problems such as malignant diseases due to microwave exposure during the use of these devices. The brain is the main target organ.
METHODS: Since the second part of the 1990s we have performed six case-control studies on this topic encompassing use of both cellular and cordless phones as well as other exposures. Three of the studies concerned brain tumours, one salivary gland tumours, one non-Hodgkin lymphoma (NHL) and one testicular cancer. Exposure was assessed by self-administered questionnaires.
RESULTS: Regarding acoustic neuroma analogue cellular phones yielded odds ratio (OR) = 2.9, 95 % confidence interval (CI) = 2.0-4.3, digital cellular phones OR = 1.5, 95 % CI = 1.1-2.1 and cordless phones OR = 1.5, 95 % CI = 1.04-2.0. The corresponding results were for astrocytoma grade III-IV OR = 1.7, 95 % CI =1.3-2.3; OR = 1.5, 95 % CI = 1.2-1.9 and OR = 1.5, 95 % CI = 1.1-1.9, respectively. The ORs increased with latency period with highest estimates using > 10 years time period from first use of these phone types. Lower ORs were calculated for astrocytoma grade I-II. No association was found with salivary gland tumours, NHL or testicular cancer although an association with NHL of T-cell type could not be ruled out.
CONCLUSION: We found for all studied phone types an increased risk for brain tumours, mainly acoustic neuroma and malignant brain tumours. OR increased with latency period, especially for astrocytoma grade III-IV. No consistent pattern of an increased risk was found for salivary gland tumours, NHL, or testicular cancer.
PMID: 17034627 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17034627&query_hl=4&itool=pubmed_docsum
--------
Seems that the media is hungry like a wolf today for the sperm study, so it is a good opportunity to push at the same time also the new review by Hardell, attached.
http://www.buergerwelle.de/pdf/tumour_risk_associated_with_use_of_cellular_telephones.pdf
Iris Atzmon.
[Epub ahead of print]
* Hardell L,
* Hansson Mild K,
* Carlberg M,
* Soderqvist F.
ABSTRACT:
BACKGROUND: The use of cellular and cordless telephones has increased dramatically during the last decade. There is concern of health problems such as malignant diseases due to microwave exposure during the use of these devices. The brain is the main target organ.
METHODS: Since the second part of the 1990s we have performed six case-control studies on this topic encompassing use of both cellular and cordless phones as well as other exposures. Three of the studies concerned brain tumours, one salivary gland tumours, one non-Hodgkin lymphoma (NHL) and one testicular cancer. Exposure was assessed by self-administered questionnaires.
RESULTS: Regarding acoustic neuroma analogue cellular phones yielded odds ratio (OR) = 2.9, 95 % confidence interval (CI) = 2.0-4.3, digital cellular phones OR = 1.5, 95 % CI = 1.1-2.1 and cordless phones OR = 1.5, 95 % CI = 1.04-2.0. The corresponding results were for astrocytoma grade III-IV OR = 1.7, 95 % CI =1.3-2.3; OR = 1.5, 95 % CI = 1.2-1.9 and OR = 1.5, 95 % CI = 1.1-1.9, respectively. The ORs increased with latency period with highest estimates using > 10 years time period from first use of these phone types. Lower ORs were calculated for astrocytoma grade I-II. No association was found with salivary gland tumours, NHL or testicular cancer although an association with NHL of T-cell type could not be ruled out.
CONCLUSION: We found for all studied phone types an increased risk for brain tumours, mainly acoustic neuroma and malignant brain tumours. OR increased with latency period, especially for astrocytoma grade III-IV. No consistent pattern of an increased risk was found for salivary gland tumours, NHL, or testicular cancer.
PMID: 17034627 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17034627&query_hl=4&itool=pubmed_docsum
--------
Seems that the media is hungry like a wolf today for the sperm study, so it is a good opportunity to push at the same time also the new review by Hardell, attached.
http://www.buergerwelle.de/pdf/tumour_risk_associated_with_use_of_cellular_telephones.pdf
Iris Atzmon.
Mast sanity - 22. Oct, 17:22
Who is funding cancer research now?
A world-class centre of excellence in Cambridge, set to speed up the delivery of new ways of diagnosing, treating and preventing cancer, has entered its final phase of development today.
Leading figures from funding bodies, key stakeholders and the construction project team will gather at the Addenbrooke¹s Hospital campus to celebrate the topping out of the University of Cambridge - Hutchison - Cancer Research UK Laboratory Building.
The £42 million project involves construction of 14,000 square metres of research laboratories which will house up to 300 scientists. Funding is provided by Cancer Research UK (£14 million) and Hutchison Whampoa Ltd (£16.5 million), with the remainder coming from the University of Cambridge and an anonymous donor.
Ray O¹Rourke, Chief Executive of Laing O¹Rourke, the main contractor, welcomed more than eighty guests to the ceremony. He said: ³We are delighted to have reached this important point of this significant construction project. We now look forward to reaching a successful conclusion of this major landmark building.²
The striking five-storey building designed by Anshen/Dyer architects, will provide open plan glass-walled research facilities, a 200-seat seminar theatre, a restaurant and an exhibition area. It will add further strength to the ground-breaking cancer research already in Cambridge. Fostering collaboration between scientists and doctors, improved approaches to cancer diagnosis treatment and prevention will be developed for the benefit of cancer patients.
Innovative research is planned, including cancer genetics and the study of the earliest stages of cancer development. Bioinformatics, which is increasingly important for analysing complex research data, will be developed jointly with the University¹s Department of Mathematical Sciences.
Professor Alison Richard, Vice Chancellor of the University of Cambridge said: "We are celebrating a significant milestone for cancer research worldwide. I am deeply appreciative of the significant funds provided for this facility by Hutchison Whampoa and Cancer Research UK. It is gratifying that these funds are a reflection of the outstanding quality of the research being done in this area at the University of Cambridge.²
Professor Bruce Ponder, Cancer Research UK Professor of Oncology, University of Cambridge said: ³I am delighted that Cambridge has again been recognised as a world leader in medical science. The partnership between the University of Cambridge and Cancer Research UK will make a unique contribution to turning cancer research into cancer treatment."
Cancer Research UK's Chief Executive, Professor Alex Markham, said: "We're very excited by the plan for the new Centre, which will put Cambridge at the forefront of cancer research not only in the UK, but indeed the world. Exciting plans for research at the Centre are already under way and we expect new cancer therapies to reach clinical trials in Cambridge as a direct result. Results from these trials should benefit cancer patients worldwide."
Sir Ka-Shing Li, Chairman of Hutchison Whampoa, commented that he is happy to make a contribution to what is clearly one of the world's most important centres for Cancer Research. He is also delighted that links between Cambridge University and Hutchison continue to strengthen in both the medical research and the general educational fields, thus contributing to the two-way flow of expertise and knowledge between Hong Kong, China and the United Kingdom.
The construction project is being managed by the University¹s Estate Management and Building Service. It is the biggest single construction project the University has ever undertaken and marks only Phase One of a two-part research development on the Addenbrooke¹s campus. Phase One began on site in July 2003, and is set to be complete in Autumn 2005. It is one of several projects made possible by the recently-opened staff multi-storey car park which has freed up land for development.
19 Apr 2004
Leading figures from funding bodies, key stakeholders and the construction project team will gather at the Addenbrooke¹s Hospital campus to celebrate the topping out of the University of Cambridge - Hutchison - Cancer Research UK Laboratory Building.
The £42 million project involves construction of 14,000 square metres of research laboratories which will house up to 300 scientists. Funding is provided by Cancer Research UK (£14 million) and Hutchison Whampoa Ltd (£16.5 million), with the remainder coming from the University of Cambridge and an anonymous donor.
Ray O¹Rourke, Chief Executive of Laing O¹Rourke, the main contractor, welcomed more than eighty guests to the ceremony. He said: ³We are delighted to have reached this important point of this significant construction project. We now look forward to reaching a successful conclusion of this major landmark building.²
The striking five-storey building designed by Anshen/Dyer architects, will provide open plan glass-walled research facilities, a 200-seat seminar theatre, a restaurant and an exhibition area. It will add further strength to the ground-breaking cancer research already in Cambridge. Fostering collaboration between scientists and doctors, improved approaches to cancer diagnosis treatment and prevention will be developed for the benefit of cancer patients.
Innovative research is planned, including cancer genetics and the study of the earliest stages of cancer development. Bioinformatics, which is increasingly important for analysing complex research data, will be developed jointly with the University¹s Department of Mathematical Sciences.
Professor Alison Richard, Vice Chancellor of the University of Cambridge said: "We are celebrating a significant milestone for cancer research worldwide. I am deeply appreciative of the significant funds provided for this facility by Hutchison Whampoa and Cancer Research UK. It is gratifying that these funds are a reflection of the outstanding quality of the research being done in this area at the University of Cambridge.²
Professor Bruce Ponder, Cancer Research UK Professor of Oncology, University of Cambridge said: ³I am delighted that Cambridge has again been recognised as a world leader in medical science. The partnership between the University of Cambridge and Cancer Research UK will make a unique contribution to turning cancer research into cancer treatment."
Cancer Research UK's Chief Executive, Professor Alex Markham, said: "We're very excited by the plan for the new Centre, which will put Cambridge at the forefront of cancer research not only in the UK, but indeed the world. Exciting plans for research at the Centre are already under way and we expect new cancer therapies to reach clinical trials in Cambridge as a direct result. Results from these trials should benefit cancer patients worldwide."
Sir Ka-Shing Li, Chairman of Hutchison Whampoa, commented that he is happy to make a contribution to what is clearly one of the world's most important centres for Cancer Research. He is also delighted that links between Cambridge University and Hutchison continue to strengthen in both the medical research and the general educational fields, thus contributing to the two-way flow of expertise and knowledge between Hong Kong, China and the United Kingdom.
The construction project is being managed by the University¹s Estate Management and Building Service. It is the biggest single construction project the University has ever undertaken and marks only Phase One of a two-part research development on the Addenbrooke¹s campus. Phase One began on site in July 2003, and is set to be complete in Autumn 2005. It is one of several projects made possible by the recently-opened staff multi-storey car park which has freed up land for development.
19 Apr 2004
Mast sanity - 22. Oct, 15:42
